Ranbaxy CY09 cons net profit at Rs 310 cr

ALSO READ News and Notices about Ranbaxy Labs See interviews with Ranbaxy Labs Management See what other Experts & Brokerages are saying about Ranbaxy Labs See previous Results of Ranbaxy Labs Ranbaxy Labs BSE | NSE 10/02/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy Laboratories , a subsidiary of Daiichi Sankyo, has announced its results for the calendar year 2009. It has reported consolidated net profit of Rs 310 crore as against loss of Rs 935 crore.

Consolidated net sales increased slightly to Rs 7,329 crore from Rs 7,224 crore.

It has reported forex loss of Rs 193 crore versus gain of Rs 1,106 crore.

In a press conference, Ranbaxy says
-Zenotech transactions likely to close this year
-Company to foray into vaccines
-Forex was positive in 2009
-To continue to invest in India, US markets
-Dewas inspection is on horizon by USFDA
-NJ facilities continue to supply
-Dewas & Ponta Sahib under FDA alert currently